HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED

Press Releases Hansoh Pharmaceutical Group Company Limited

Equities

3692

KYG549581067

Market Closed - Hong Kong S.E. Other stock markets 04:08:17 2024-05-07 EDT			5-day change	1st Jan Change
18.32 ^HKD	+0.11%		+5.29%	+16.24%

04-30	Hansoh Pharmaceutical’s 2023 Profit Up 27%	MT
04-29	Hansoh Pharmaceutical Group Company Limited Announces Executive Changes, Effective April 29, 2024	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

2023 CTOS, Hansoh Pharma HS-20093 Phase II clinical study design was selected into the International Connective Tissue Oncology Conference	01-24	AQ
Hansoh Pharmaceutical Group Co., Ltd. - The 24th China Patent Awards Ceremony was held, and Hansoh Pharma's Ametinib patent was awarded the China Patent Gold Award	23-10-19	AQ
Hansoh Pharmaceutical's Saint Relais is the first batch to be shipped nationwide, bringing a safe and long-lasting new option to CKD patients with renal anemia	23-09-25	AQ
SCYNEXIS and Hansoh Pharma Announce NMPA Acceptance of the New Drug Application for Ibrexafungerp in China	23-07-20	AQ
KiOmed Pharma and Hansoh Pharma Announce License Agreement for KioMedinevsone in China's Mainland, Macau and Taiwan	22-09-27	AQ
Hansoh Pharmaceutical : FINAL DIVIDEND FOR THE YEAR ENDED DECEMBER 31, 2021	22-03-29	PU
Hansoh Pharmaceutical : Pharma and OliX Pharmaceuticals Enter into Licensing and Collaboration Agreement to Develop and Commercialize siRNA Therapeutics in Greater China	21-10-12	AQ
SCYNEXIS : Announces Hansoh Pharma's Application to National Medical Products Administration (NMPA) in China for Phase 3 Trial of Ibrexafungerp for Treatment of Vulvovaginal Candidiasis (VVC)	21-09-14	AQ
SCYNEXIS : Announces Hansoh Pharma’s Application to National Medical Products Administration (NMPA) in China for Phase 3 Trial of Ibrexafungerp for Treatment of Vulvovaginal Candidiasis (VVC)	21-09-13	AQ
Hansoh Pharmaceutical : Accelerate Benefits for Hepatitis B Patients! Hansoh Pharma's New Class 1 Drug Hengmu (Tenofovir Amibufenamide Tablets) Prescribed for the First Time in China	21-07-06	AQ
Hansoh Pharmaceutical : VOLUNTARY ANNOUNCEMENT - NEW DRUG APPLICATION OF AMEILE IN FIRST LINE EGFR-MUTATED NON-SMALL CELL LUNG CANCER ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION	21-05-13	PU
Hansoh Pharmaceutical : VOLUNTARY ANNOUNCEMENT - FDA TENTATIVE APPROVAL OF "BORTEZOMIB FOR INJECTION"	21-05-10	PU
Hansoh Pharmaceutical : FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON THURSDAY, JUNE 3, 2021	21-04-27	PU
Hansoh Pharmaceutical : VOLUNTARY ANNOUNCEMENT - DRUG REGISTRATION APPROVAL OF "LENALIDOMIDE CAPSULE"	21-04-01	PU
Hansoh Pharmaceutical : VOLUNTARY ANNOUNCEMENT - DRUG REGISTRATION APPROVAL OF "EMPAGLIFLOZIN TABLETS"	20-07-31	PU
Hansoh Pharmaceutical : INSIDE INFORMATION - LICENSE AGREEMENT WITH EQRX	20-07-22	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Stock Market
Equities
3692 Stock
News Hansoh Pharmaceutical Group Company Limited
Press Releases

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

SIGN UP NOW